
    
      Phase II non comparative study, assessing the safety (primarily cardiac safety) and efficacy
      in patients with locally advanced or metastatic HER2/neu positive breast cancer not yet
      treated with chemotherapy for metastatic disease.

      Myocet and Taxotere will be given for a maximum of 6 cycles, Herceptin treatment for 1 year
      is recommended.

      Endpoints: cardiotoxicity (left ventricular ejection fraction decrease and/or symptoms of
      heart failure), serious other toxicity, disease progression.
    
  